Open this publication in new window or tab >>Department of Cardiology , Sahlgrenska University Hospital, the Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Medical Sciences Cardiology, Uppsala University, Uppsala, Sweden.
Department of Cardiology, Sahlgrenska University Hospital, the Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Clinical Sciences Lund, Rheumatology, Lund University, and the Rheumatology Clinic, Skåne University Hospital, Lund, Sweden.
Region Östergötland, Heart and Medicine Center, Department of Cardiology in Linköping. Region Östergötland, Heart and Medicine Center, Department of Clinical Physiology in Linköping.
Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden; Haemodynamic Laboratory, the Section for Heart Failure and Valvular Disease, VO Heart and Lung Medicine, Skåne University Hospital, Lund, Sweden.
Department of Medicine, Karolinska Institute, Stockholm, Sweden; Clinic for Pulmonary Medicine, Karolinska University Hospital, Stockholm, Sweden.
Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden; Haemodynamic Laboratory, the Section for Heart Failure and Valvular Disease, VO Heart and Lung Medicine, Skåne University Hospital, Lund, Sweden.
Department of Medicine, Karolinska Institute, Stockholm, Sweden; Clinic for Pulmonary Medicine, Karolinska University Hospital, Stockholm, Sweden .
Department of Public Health and Clinical Medicine, Cardiology and the Heart Centre, Umeå University, Umeå, Sweden.
Department of Cardiology, Karolinska Institute, Stockholm, Sweden; Department of Cardiology, Södersjukhuset, Sweden, Stockholm.
Department of Clinical Physiology, Örebro University, and Örebro University Hospital, Örebro, Sweden.
Department of Medical Sciences Cardiology, Uppsala University, Uppsala, Sweden.
Department of Medical Sciences Cardiology, Uppsala University, Uppsala, Sweden.
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Heart and Medicine Center, Department of Clinical Physiology in Linköping. Region Östergötland, Heart and Medicine Center, Department of Cardiology in Linköping.
Department of Medicine, Karolinska Institute, Stockholm, Sweden; Clinic for Pulmonary Medicine, Karolinska University Hospital, Stockholm, Sweden.
Show others...
2016 (English)In: Scandinavian Cardiovascular Journal, ISSN 1401-7431, E-ISSN 1651-2006, Vol. 50, no 4, p. 243-250Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: The Swedish Pulmonary Arterial Hypertension Register (SPAHR) is an open continuous register, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients from 2000 and onwards. We hereby launch the first data from SPAHR, defining baseline characteristics and survival of Swedish PAH and CTEPH patients.
DESIGN: Incident PAH and CTEPH patients 2008-2014 from all seven Swedish PAH-centres were specifically reviewed.
RESULTS: There were 457 PAH (median age: 67 years, 64% female) and 183 CTEPH (median age: 70 years, 50% female) patients, whereof 77 and 81%, respectively, were in functional class III-IV at diagnosis. Systemic hypertension, diabetes, ischaemic heart disease and atrial fibrillation were common comorbidities, particularly in those >65 years. One-, 3- and 5-year survival was 85%, 71% and 59% for PAH patients. Corresponding numbers for CTEPH patients with versus without pulmonary endarterectomy were 96%, 89% and 86% versus 91%, 75% and 69%, respectively. In 2014, the incidence of IPAH/HPAH, associated PAH and CTEPH was 5, 3 and 2 per million inhabitants and year, and the prevalence was 25, 24 and 19 per million inhabitants.
CONCLUSION: The majority of the PAH and CTEPH patients were diagnosed at age >65 years, in functional class III-IV, and exhibiting several comorbidities. PAH survival in SPAHR was similar to other registers.
Place, publisher, year, edition, pages
Taylor & Francis, 2016
Keywords
Incident, prevalent, pulmonary hypertension, survival
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-130206 (URN)10.1080/14017431.2016.1185532 (DOI)000379819900008 ()27146648 (PubMedID)
Note
Funding agencies: Actelion Pharmaceuticals Sweden AB; Bayer Health Care; Eli Lilly Sweden; Glaxo-SmithKline; Nordicinfu Care; Pfizer; SALAR (SKL); "ALF" foundations
2016-07-142016-07-142018-03-20Bibliographically approved